Rampart Bioscience
NEWS
Six biotechs based in California, Massachusetts, Washington and Denmark had to halt drug development efforts this year. One of their CEOs is now in an interim chief executive role at another biotech.
Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
IN THE PRESS
JOBS